Genetic Influences on Pharmacological Interventions in Psoriasis

Abstract

Psoriasis is a common chronic inflammatory disease that affects 2% of the population. Therapeutic intervention for psoriasis mainly targets inflammatory cascade through the use of topical agents, phototherapy, systemic agents and the newer biologic agents. The efficacy of many treatments used in psoriasis varies from patient to patient, and some of this variance in response can presumably be attributed to genetic differences. While current research findings are still limited, the clinical utilization of pharmacogenetics allows for tailored treatment plans that have the potential for better response amongst patients as well as conserving expenditures and healthcare resources. In this review, we hope to focus and summarize the conclusions and findings of studies done on the topic of pharmacogenetics in the treatment of psoriasis.

HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis

“…The SNP array analysis thus identified 417 genetic variants in total. The analyzed SNPs were selected based on an extensive review of articles on the association between psoriasis and SNPs or response to biologics [9,15,[20][21][22][23][24][25][26][27].…”

“…42.9 (6) 57.1 (8) 71.4 (10) 81.3 (39) 95.7 (44) 81.8 (18) 85.2 (23) 83.8 (31) 87.8 (36) 86.9 (40) 87.5 (42) 91.7 36.4 (4) 50.0 (6) 53.8 (7) 42.9 (6) 35.7 (5) 50.0 (7) 58.3 (28) 84.8 (39) 68.2 (15) 74.1 (20) 75.7 (28) 82.9 (34) 80.4 (37) 83.3 (40) 83 31.3 (15) 65.2 (30) 50.0 (11) 48.1 (13) 59.5 (22) 68.3 (28) 67.4 (31) 70.8 (34) 62.5 Figure 2. Association analysis between rs9267325 SNP and clinical response to secukinumab.…”